Anti-Human/Mouse Mac-2 (Galectin-3) (Clone M3/38 ) – Purified No Carrier Protein

Anti-Human/Mouse Mac-2 (Galectin-3) (Clone M3/38 ) – Purified No Carrier Protein

Product No.: M360

- -
- -
Clone
M3/38
Target
Mac-2 (Galectin-3)
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
Gal-3, RL-29, galactose-specific lectin 3, CBP-35, L-34
Isotype
Rat IgG2a κ
Applications
ELISA
,
FC
,
IF
,
IHC
,
IP
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human/Mouse
Host Species
Rat
Immunogen
Raised against galectin-3 of mouse origin
Product Concentration
≥1.0 mg/ml
Purity
≥90% monomer by analytical SEC and SDS-Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
State of Matter
Liquid
Storage and Handling
This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
ELISA,
FC,
IF,
IHC,
IP,
WB
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
M3/38 activity is directed against human and mouse Mac-2 (Galectin-3).
Background
Mac-2 (Galectin-3) is a β-galactoside-binding lectin of the chimera-type, characterized by a single carbohydrate recognition domain and an N-terminal polypeptide tail region1. Mac-2 plays important roles in cell proliferation, apoptotic regulation, cell-to-cell and cell-to-matrix interactions, macrophage activation, angiogenesis, inflammation, fibrosis and host defense. Additionally, Mac-2 is an early-stage diagnostic and/or prognostic biomarker for viral infection, neurodegenerative disorders, tumor formation, diabetes mellitus, and certain types of heart, kidney, and autoimmune disease. The primary structure of mouse and human Mac-2 is highly conserved with 85% similarity2. Human Mac-2 binds to asialofetuin and purified laminin.

M3/38 was generated by immunizing rats with immunoadsorbent-purified macrophage glycoproteins and fusing the resulting spleen cells with mouse myeloma cells3. M3/38 is able to immunoprecipitate both the mouse and human Mac-2 homologs2,3. M3/38 binding to Mac-2 can be inhibited by galactose2. M3/38 recognizes a linear epitope within the N-terminal domain of Mac-24. The common minimal sequence as determined by SPOT analysis as Ala-Pro-Pro-Gly-Ala-Tyr.

M3/38 has been exploited for live cell thyroid tumor imaging4,5. A chimeric M3/38 Fab-fragment and its humanized derivative can detect Mac-2 overexpression in cancerous thyroid nodules in mice via positron emission tomography. The three-dimensional structure of the rat/human chimeric Fab has been determined5.
Antigen Distribution
Mac-2 (Galectin-3) is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. Mac-2 is secreted into fluids such as serum and urine as well as released by injured and inflammatory cells. Mac-2 was originally identified in murine inflammatory macrophages. Mac-2 is also expressed by various cell lines (e.g., HeLa, SL68, HL60, HT29).
NCBI Gene Bank ID
UniProt.org
Research Area
Cell Biology
.
Immunology

References & Citations

1 Hara A, Niwa M, Noguchi K, et al. Biomolecules. 10(3):389. 2020.
2 Cherayil BJ, Chaitovitz S, Wong C, et al. Proc Natl Acad Sci U S A. 87(18):7324-7328. 1990.
3 Ho MK, Springer TA. J Immunol. 128(3):1221-1228. 1982.
4 Peplau E, De Rose F, Eichinger A, et al. Sci Rep. 11(1):7358. 2021.
5 Peplau E, De Rose F, Reder S, et al. Thyroid. 30(9):1314-1326. 2020.
6 Flotte TJ, Springer TA, Thorbecke GJ. Am J Pathol. 111(1):112-24. 1983.
7 Nibbering PH, Leijh PC, van Furth R. Cell Immunol. 105(2):374-385. 1987.
8 Nibbering PH, Leijh PC, van Furth R. Immunology. 62(2):171-176. 1987.
9 Nibbering PH, van Furth R. Immunobiology. 176(4-5):432-439. 1988.
10 Nibbering PH, van der Heide A, van Furth R. J Pathol. 157(3):253-261. 1989.
11 Toussaint-Demylle D, Many MC, Theisen H, et al. Autoimmunity. 7(1):51-62. 1990.
12 Knisley KA, Weitlauf HM. J Reprod Fertil. 97(2):521-527. 1993.
13 Dumić J, Lauc G, Hadzija M, et al. Z Naturforsch C J Biosci. 55(3-4):261-266. 2000.
14 Mey A, Berthier-Vergnes O, Apoil PA, et al. Cancer Lett. 81(2):155-163. 1994.
15 Nachtigal M, Al-Assaad Z, Mayer EP, et al. Am J Pathol. 152(5):1199-1208. 1998.
16 Piantelli M, Iacobelli S, Almadori G, et al. J Clin Oncol. 20(18):3850-3856. 2002.
17 Schaffert C, Pour PM, Chaney WG. Int J Pancreatol. 23(1):1-9. 1998.
18 Dumic J, Lauc G, Flögel M. Cell Physiol Biochem. 10(3):149-158. 2000.
19 Dumić J, Barisić K, Flögel M, et al. Stress. 3(3):241-246. 2000.
20 Mey A, Leffler H, Hmama Z, et al. J Immunol. 156(4):1572-1577. 1996.
Indirect Elisa Protocol
Flow Cytometry
IF
IHC
Immunoprecipitation Protocol
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.